Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2011

01-08-2011 | Original Paper

Assessing the value of CAN-gene mutations using MALDI-TOF MS

Authors: Corina Kohler, Björn Tavelin, Alex Xiu-Cheng Fan, Ramin Radpour, Zeinab Barekati, Fabio Levi, Xiao Yan Zhong, Per Lenner, Paolo Toniolo

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2011

Login to get access

Abstract

Purpose

To identify cancer-linked genes, Sjöblom et al. and Wood et al. performed a genome-wide mutation screening in human breast and colorectal cancers. 140 CAN-genes were found in breast cancer, which in turn contained overall 334 mutations. These mutations could prove useful for diagnostic and therapeutic purposes.

Methods

We used a MALDI-TOF MS 40-plex assay for testing 40 loci within 21 high-ranking breast cancer CAN-genes. To confirm mutations, we performed single-plex assays and sequencing.

Results

In general, the mutation rate of the analyzed loci in our sample cohort was very low. No mutation from the 40 loci analyzed could be found in the 6 cell lines. In tissue samples, a single breast cancer tissue sample showed heterozygosity at locus c.5834G>A within the ZFYVE26 gene (Zinc finger FYVE domain-containing gene 26).

Conclusions

Sjöblom et al./Wood et al. already showed that the vast majority of CAN-genes are mutated at very low frequency. Due to the fact that we only found one mutation in our cohort, we therefore assume that at the selected loci, mutations might be low-frequency events and therefore, more rarely detectable. However, further evaluation of the CAN-gene mutations in larger cohorts should be the aim of further studies.
Appendix
Available only for authorised users
Literature
go back to reference Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J (2000) Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923–3931PubMed Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J (2000) Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923–3931PubMed
go back to reference Collins FS, McKusick VA (2001) Implications of the human genome project for medical science. JAMA 285:540–544PubMedCrossRef Collins FS, McKusick VA (2001) Implications of the human genome project for medical science. JAMA 285:540–544PubMedCrossRef
go back to reference Garritsen HS, Fan AX, Bosse N, Hannig H, Kelsch R, Kroll H et al (2009) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for genotyping of human platelet-specific antigens. Transfusion 49:252–258PubMedCrossRef Garritsen HS, Fan AX, Bosse N, Hannig H, Kelsch R, Kroll H et al (2009) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for genotyping of human platelet-specific antigens. Transfusion 49:252–258PubMedCrossRef
go back to reference Goizet C, Boukhris A, Maltete D, Guyant-Marechal L, Truchetto J, Mundwiller E et al (2009) SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. Neurology 73:1111–1119PubMedCrossRef Goizet C, Boukhris A, Maltete D, Guyant-Marechal L, Truchetto J, Mundwiller E et al (2009) SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. Neurology 73:1111–1119PubMedCrossRef
go back to reference Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S et al (2005) Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 65:439–447PubMed Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S et al (2005) Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 65:439–447PubMed
go back to reference Sagona AP, Nezis IP, Pedersen NM, Liestol K, Poulton J, Rusten TE et al (2010) PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. Nat Cell Biol 12:362–371PubMedCrossRef Sagona AP, Nezis IP, Pedersen NM, Liestol K, Poulton J, Rusten TE et al (2010) PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. Nat Cell Biol 12:362–371PubMedCrossRef
go back to reference Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedCrossRef Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedCrossRef
go back to reference Soussi T, Lozano G (2005) p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331:834–842PubMedCrossRef Soussi T, Lozano G (2005) p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331:834–842PubMedCrossRef
go back to reference The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678CrossRef The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678CrossRef
go back to reference Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351PubMedCrossRef Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351PubMedCrossRef
go back to reference Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al (2001) The sequence of the human genome. Science 291:1304–1351PubMedCrossRef Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al (2001) The sequence of the human genome. Science 291:1304–1351PubMedCrossRef
go back to reference Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388PubMedCrossRef Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388PubMedCrossRef
go back to reference Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113PubMedCrossRef Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113PubMedCrossRef
go back to reference Xiu-Cheng Fan A, Garritsen HS, Tarhouny SE, Morris M, Hahn S, Holzgreve W et al (2008) A rapid and accurate approach to identify single nucleotide polymorphisms of mitochondrial DNA using MALDI-TOF mass spectrometry. Clin Chem Lab Med 46:299–305PubMedCrossRef Xiu-Cheng Fan A, Garritsen HS, Tarhouny SE, Morris M, Hahn S, Holzgreve W et al (2008) A rapid and accurate approach to identify single nucleotide polymorphisms of mitochondrial DNA using MALDI-TOF mass spectrometry. Clin Chem Lab Med 46:299–305PubMedCrossRef
Metadata
Title
Assessing the value of CAN-gene mutations using MALDI-TOF MS
Authors
Corina Kohler
Björn Tavelin
Alex Xiu-Cheng Fan
Ramin Radpour
Zeinab Barekati
Fabio Levi
Xiao Yan Zhong
Per Lenner
Paolo Toniolo
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-0990-4

Other articles of this Issue 8/2011

Journal of Cancer Research and Clinical Oncology 8/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.